Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1095

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma (FL)

Interventions

DRUG: Epcoritamab
DRUG: Prednisone
DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Cyclophosphamide
DRUG: Obinutuzumab
DRUG: Bendamustine

Sponsor

Genmab

Collaborators

[object Object]